WOODBRIDGE, ON, Aug. 28, 2012 /PRNewswire/ - Pivotal Therapeutics Inc. (OTCQX: PVTTF) (CNSX: PVO), a specialty pharmaceutical company with a focus on cardiovascular
disease and overall health today announced its financial results and
operational highlights for the quarter ended ended June 30, 2012. All
dollar amounts referenced herein are in Canadian dollars unless
For the three months ended June 30, 2012 the Company reported a loss of
$874,313, or $0.01 per common share, compared with a loss of $1,757,505
or $0.03 per common share for the three months ended June 30, 2011. At
June 30, 2012, Pivotal's cash position totaled $84,448, compared with
$1,586,653 at December 31, 2011. The decrease in cash during the six
months ended June 30, 2012, is primarily due to an increase in sales
and marketing programs of VASCAZEN, and an increased investment in product inventory.
"We are pleased with the ongoing progress in the commercialization of VASCAZEN and are focused on the continuing education of physicians and patients
on the benefits of VASCAZEN," stated Rachelle MacSweeney, Pivotal's President and Chief Operating
Officer. "The recent investment in the Company, by a U.S. Institutional
Fund, will further these efforts and allow us to achieve the goals we
have set out for the marketplace."
Highlights for 2012:
- April 3, 2012 - the Company began trading in the U.S. on the OTC
Markets' QX Marketplace, under the symbol PVTTF;
- April 30, 2012 - the Company announced its 2011 financial results;
- May 22, 2012 - the Company announced first prescription sales in the
- May 28, 2012 - the Company announced its Q1 financial results;
- June 25, 2012 - the Company announced U.S. Institutional Private
Placement for $5M CDN;
- August 8, 2012 - the Company announced a scientific study demonstrating
superiority of its lead product VASCAZEN.
Pivotal's Goals for 2012:
Further commercialization of VASCAZEN in the U.S.;
Expansion of the sales & marketing team;
Initiation of new clinical trials;
Completion of existing clinical trials for VASCAZEN and publication of scientific data;
Expansion of intellectual property portfolio;
Investigation of international licensing opportunities;
Expansion of product offerings;
Investment community presentations to increase awareness and
Presentations and attendance at scientific meetings.
The unaudited consolidated financial statements, accompanying notes and
Management's Discussion and Analysis for the three and six months ended
June 30, 2012, are accessible on Pivotal's website at www.pivotaltherapeutics.us and on SEDAR (www.sedar.com).
About Pivotal Therapeutics Inc.
With offices in Toronto, Canada and Boca Raton, Florida, Pivotal
Therapeutics is a publicly traded (OTCQX: PVTTF); (CNSX: PVO) specialty
pharmaceutical company with a focus on cardiovascular disease and
overall health. Pivotal Therapeutics' lead product VASCAZENTM is a prescription only Medical Food formulated to meet the dietary
Omega-3 deficient needs of patients with cardiovascular disease through
elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to
levels associated with reduced risk of cardiovascular complications.
VASCAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation, protected
by a series of both issued and pending US and foreign patents and
commercialized as a prescription only Medical Food. This unique
formulation will provide the cornerstone upon which a family of cutting
edge combination products, with efficacy across a broad spectrum of
cardiac care, will be commercialized.
OMAZENTM is a >90% pure, proprietary EPA:DHA fatty acid formulation
commercialized for sale and distribution in Canada for the maintenance
of good health through elevating Omega-3 fatty acid levels. The unique
formulation and dosage will be available to patients and consumers who
realize the health benefits of Omega-3 supplementation with a quality
The information contained in this document is as of August 28, 2012.
This press release contains forward-looking statements. Such
forward-looking statements are subject to a number of risks,
assumptions and uncertainties that could cause Pivotal's actual results
to differ materially from those projected in such forward-looking
statements. These statements can be identified by the use of words such
as "will", "anticipate", "estimate", "expect", "project", "forecast",
"intend", "plan", "believe", "project", "potential", and similar
expressions with any discussion of future operating or financial
performance or events. In particular, factors that could cause actual
results to differ materially from those in forward looking statements
include the following: Pivotal's inability to obtain additional
financing on acceptable terms; growth in costs and expenses; inability
to compete with others who provide comparable products; risk that the
Company's products will not gain widespread market acceptance; risks
relating to the Company's ability to maintain its CSNX listing.
Forward-looking statements speak only as of the date made and are not
guarantees of future performance. The Company undertakes no obligation
to publicly update or revise any forward-looking statements contained
in this document as a result of new information or future events or
developments. CNSX has not reviewed and does not accept responsibility
for the adequacy or accuracy of this information.
SOURCE Pivotal Therapeutics Inc.